Robert Mah

USPTO Granted Patents = 48 (Patent Applications = 17)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 28 (Patent Applications = 28)

Average Co-Inventor Count = 6.9

ph-index = 6

Forward Citations = 96(Granted Patents)

Location History:

Allschwil, CH (1997 - 2012)
Basel, CH (1998 - 2013)
Muttenz, CH (2009 - 2020)
Muenchenstein, CH (2023)

Company Filing History:

Speedel Experimenta Ag

Ciba-geigy Corporation

Years Active: 1997-2023

where 'Filed Patents' based on already Granted Patents

48 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11702409 - Pyrazolyl derivatives useful as anti-cancer agents (2023-07-18),

2. 10786492 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors (2020-09-29),

3. 10507201 - Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2019-12-17),

4. 10189813 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors (2019-01-29),

5. 10130629 - Pharmaceutical combinations (2018-11-20),

6. 9896449 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2018-02-20),

7. 9802917 - Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (2017-10-31),

8. 9556180 - Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction (2017-01-31),

9. 9533988 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2017-01-03),

10. 9403827 - Substituted purinone compounds (2016-08-02),

11. 9365576 - Pyrrolopyrrolidinone compounds (2016-06-14),

12. 9266883 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2016-02-23),

13. 8969341 - Pyrazolopyrrolidine compounds (2015-03-03),

14. 8815926 - Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases (2014-08-26),

15. 8680079 - Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors (2014-03-25),

Title: Robert Mah: A Pioneer in Anti-Cancer Drug Development

Introduction: Robert Mah, based in Muttenz, Switzerland, is a prominent inventor and researcher known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 47 patents, Mah has dedicated his career to developing innovative compounds aimed at treating various medical conditions, particularly cancer.

Latest Patents: Among Robert Mah's latest inventions are groundbreaking compounds with potential therapeutic applications. One notable patent concerns Pyrazolyl derivatives that serve as anti-cancer agents. This invention encompasses a compound of formula (I) or its stereoisomers, along with methods of manufacturing and therapeutic uses. Furthermore, it outlines combinations of pharmacologically active agents, enhancing the potential efficacy of cancer treatments.

Another significant invention by Mah includes Formylated N-heterocyclic derivatives that act as fibroblast growth factor receptor 4 (FGFR4) inhibitors. This patent also provides a compound of formula (I), methods for its manufacture, and its therapeutic uses, along with combinations of active agents and pharmaceutical compositions.

Career Highlights: Robert Mah has had a distinguished career, contributing to innovative research and development in the pharmaceutical industry. He has worked with renowned companies such as Novartis AG and Speedel Experimenta AG. His work has been crucial in advancing the development of new therapies, particularly in oncology.

Collaborations: Throughout his career, Robert Mah has collaborated with talented individuals, including Peter Herold and Vincenzo Tschinke. These partnerships have fostered a climate of creativity and innovation, facilitating the development of cutting-edge pharmaceutical compounds.

Conclusion: Robert Mah's contributions to the field of cancer treatment signify his role as an influential inventor in pharmaceutical research. With a robust patent portfolio and collaborative spirit, he continues to drive innovation, aiming to improve therapeutic outcomes for patients facing challenging medical conditions. His latest inventions exemplify his commitment to advancing science and enhancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.